BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Verva Pharmaceuticals CEO an Invited Panelist at the GTCBIO 4th Annual Metabolic Diseases World Summit


10/31/2008 3:04:45 PM

Geelong, Australia (31st October, 2008). Verva Pharmaceuticals Ltd. announced today that CEO Vince Wacher will be an invited panelist in the "Partnering and Licensing" panel discussion at the GTCbio 4th Annual Metabolic Diseases World Summit. The panel will be moderated by Mike McCully, Senior Manager at Deloitte Recap LLC. Other confirmed panelists are Dr. Robert Knowles, Senior Director, Worldwide Business Development, Pfizer, Inc. and Dr. David Glass, Director, Technology Transfer, Joslin Diabetes Center. The panel discussion will take place at 5:00 pm US EST on Thursday 6th November, 2008 at Le Meridien Hotel in Cambridge, Massachusetts. Conference details can be found at www.gtcbio.com.

About Verva

Verva Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company developing novel therapies to treat diabetes and to prevent and treat obesity. Verva's lead product VVP808 is a non-thiazolidinedione insulin sensitizer entering phase 1b/2a clinical safety and efficacy testing in type 2 diabetes. VVP808 was previously approved in North America in an unrelated indication; its unexpected anti-diabetic activity was identified by Verva using the MRU-developed GES platform. Verva's pipeline includes: (i) an accelerated discovery program developing next-generation diabetes therapies based on VVP808 structure and mode-of-action; (ii) expansion of the GES platform to discover new types of optimized diabetes therapies; and (iii) preclinical proof-of-concept with two obesity-focused technologies that block de novo fat formation. Further information can be found on the company's website www.vervapharma.com.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES